Limited Role for Fibroblast Growth Factor 23 in Assessing Prognosis in Heart Failure Patients: Data from the TIME-CHF Trial
Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Hans‐Peter Brunner‐La Rocca(Inserm), Vincent Brandenburg(RWTH Aachen University), Micha T. Maeder(Kantonsspital St. Gallen), Sandra Sanders‐van Wijk(University Medical Center), Urs Jeker(Luzerner Kantonsspital), Alexander Schuh, Gregor Leibundgut(University Hospital of Basel), Matthias Pfisterer(University Hospital of Basel), Gunnar H. Heine(Agaplesion Markus Hospital)
Cited by 25
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
|The Lancet|2007|1.4k
The Use of Diuretics in Heart Failure with Congestion — A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2019|1.1k
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
|JAMA|2014|982
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755